“ As the only country in the G8 without an orphan drugs act, the President of Médunik, a company focused on bringing orphan drugs into the country,… ”
In Conversation
“ An interesting perspective on the Canadian market, and its opportunities and challenges in drug registration on a regional level from the President of Triton Pharma, a… ”
“ The CEO of Bellus Health outlines his strategy since 2010 to change the focus of the company from Alzheimer’s to a niche disease, AA amyloidosis, as… ”
“ The CEO of MaRS Innovation, a commercialization incubator created by 16 of Toronto's best research institutions and supported by the government, assesses Toronto's merits as an… ”
“ Minister Marceau addresses the changes in policy in Quebec relating to the pharmaceutical and life sciences sectors, and the incentives in place to make the state… ”
“ A perspective from Canada’s national health body on the future of medicine in the 21st century, from the shift to personalized medicine to streamlining regulatory and… ”
“ The President & CEO of Sanofi Canada talks candidly about the pros and cons of the current administrative setup of the Canadian healthcare sector; Concerto, an… ”
“ Having only arrived on the market last year, the GM of Almirall in Canada explains the company's regulatory struggles, the utilization of Almirall’s global R&D infrastructure… ”
“ BIOTECanada is the national trade association for Canada’s biotech industry. Andrew Casey, the group’s CEO, discusses the impact of IP regulation on emerging biotech companies, incentives… ”
World Courier's national operations manager in Canada covers the topics of moving to GxP standards, and the logistics challenges faced by being a logistics company in…
“ Dr. Youssef Benanni, before becoming Site Head and VP of R&D, worked as a Sr. Group leader with Abbott before moving on to being Sr. Director… ”
“ Dr. Youssef Benanni, before becoming Site Head and VP of R&D, worked as a Sr. Group leader with Abbott before moving on to being Sr. Director… ”
